ERBB2 and aneurysmal bone cyst: ET in combination with CDK4/6 inhibitors (CDK4/6i) has become the standard-of-care for first- or second-line treatment of ER-positive/HER2-negative ABC, due to their efficacy results, toxicity profile and quality of life data [I, A].